Citius Pharmaceuticals (CTXR) Non-Current Assets (2014 - 2026)
Citius Pharmaceuticals' (CTXR) quarterly Non-Current Assets came in at $100.9 million in Q1 2026, down 2.18% YoY from $103.1 million in Q1 2025, and down 1.55% on a QoQ basis from $102.4 million in Q4 2025.
Citius Pharmaceuticals (CTXR) Non-Current Assets (2014 - 2026) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 13 years of Non-Current Assets data on file, last reported at $100.9 million in Q1 2026.
- Quarterly Non-Current Assets fell 2.18% year-over-year to $100.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $409.4 million (up 8.59% YoY) and the FY2025 annual result came in at $103.0 million, up 0.56% from the prior year.
- Non-Current Assets fell to $100.9 million in Q1 2026, from $102.4 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $103.1 million in Q1 2025 to a low of $69.1 million in Q2 2024.
- A 5-year average of $83.0 million and a median of $69.5 million in 2022 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets soared 134.28% — and 2026, when it decreased 2.18%.
- Tracing CTXR's Non-Current Assets over 5 years: stood at $69.4 million in 2022, then dropped by 0.29% to $69.2 million in 2023, then soared by 47.96% to $102.4 million in 2024, then gained by 0.07% to $102.4 million in 2025, then retreated by 1.55% to $100.9 million in 2026.
- The last three Non-Current Assets figures came in at $100.9 million (Q1 2026), $102.4 million (Q4 2025), and $103.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Citius Pharmaceuticals | 15.71 Mn | 15.71 Mn | 1.00 Mn | 98.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 100.85 Mn |
| Dec 31, 2025 | 102.45 Mn |
| Sep 30, 2025 | 103.00 Mn |
| Jun 30, 2025 | 103.07 Mn |
| Mar 31, 2025 | 103.11 Mn |
| Dec 31, 2024 | 102.38 Mn |
| Sep 30, 2024 | 102.43 Mn |
| Jun 30, 2024 | 69.08 Mn |
| Mar 31, 2024 | 69.14 Mn |
| Dec 31, 2023 | 69.19 Mn |
| Sep 30, 2023 | 69.24 Mn |
| Jun 30, 2023 | 69.29 Mn |
| Mar 31, 2023 | 69.34 Mn |
| Dec 31, 2022 | 69.39 Mn |
| Sep 30, 2022 | 69.44 Mn |
| Jun 30, 2022 | 69.48 Mn |
| Mar 31, 2022 | 69.53 Mn |
| Dec 31, 2021 | 69.57 Mn |
| Sep 30, 2021 | 69.61 Mn |
| Jun 30, 2021 | 29.66 Mn |